LY
Lyell Immuno
LYEL·NASDAQS San Francisco CAFounded 2018400 employees
Small CapbiotechPublicOncology
Platform: T-cell Reprog
Market Cap
$0.8B
All Drugs
2
Clinical Trials
2
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (LYEL)
Loading LYEL stock data...
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Tiracapivasertib | LYE-7669 | Phase 2 | 1 | JAK1 | SMARB | ||
| Darasacituzumab | LYE-5876 | Phase 1 | 1 | MALT1 | CSUCLL |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (1)